Abstract
We investigated the effect of adenovirally mediated overexpression of adenylyl cyclase type 6 (AC6), a major form of AC expressed in mammalian heart, on G protein-coupled receptor regulation of cAMP production in neonatal rat ventricular myocytes. Following gene transfer of AC6, isoproterenol- and forskolin-stimulated increases in cAMP were markedly enhanced, whereas basal levels of cAMP and responses to several other agonists that stimulate cAMP formation, e.g., prostaglandin E2 (PGE2), H2agonist, glucagon, and A2 agonist were not increased. Studies to test whether the selective enhancement in β-adrenergic receptor (AR) response might result from inhibition of AC6 by Gαi and Gβγ indicated that pertussis toxin-sensitive inhibition by the muscarinic cholinergic agonist carbachol was unaltered in myocytes overexpressing AC6. Pertussis toxin treatment failed to reveal an enhancement by AC6 overexpression of basal or PGE2-stimulated cAMP. Immunoblot analysis of membrane fractions indicated that β1-AR and AC6 are expressed in fractions enriched in caveolin-3 and morphologic caveolae. The data suggest that loss of Gi-mediated inhibition is not the mechanism for enhancement of β-AR-stimulated cAMP formation and that key components of β-AR-mediated activation of AC exist in caveolae of cardiac myocytes, providing a means by which β-AR response is selectively enhanced by increasing AC6 expression.
Footnotes
-
Send reprint requests to: Paul A. Insel, M.D., Dept. of Pharmacology, 0636, University of California, San Diego, La Jolla, CA. E-mail: pinsel{at}ucsd.edu
-
↵1 These authors contributed equally to this work.
-
This work was supported by research and training grants from the National Institutes of Health.
- Abbreviations:
- AC
- adenylyl cyclase
- AC5 and AC6
- AC types 5 and 6
- PGE2
- prostaglandin E2
- HA
- hemagglutinin
- AR
- adrenergic receptor
- GFP
- green fluorescent protein
- Received December 16, 1999.
- Accepted February 7, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
